Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia

Jian-Xiong An,1– 3 John P Williams,4 Qi-Wu Fang,1 Yong Wang,1 Hui Liu,1 Le Shi,5 Wen-Hao Zhang1,2 1Department of Anesthesiology, Pain and Sleep Medicine, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: An JX, Williams JP, Fang QW, Wang Y, Liu H, Shi L, Zhang WH
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/7843809bcfcf4534b3a414c93de30206
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7843809bcfcf4534b3a414c93de30206
record_format dspace
spelling oai:doaj.org-article:7843809bcfcf4534b3a414c93de302062021-12-02T12:12:34ZFeasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia1179-1608https://doaj.org/article/7843809bcfcf4534b3a414c93de302062020-11-01T00:00:00Zhttps://www.dovepress.com/feasibility-of-patient-controlled-sleep-with-dexmedetomidine-in-treati-peer-reviewed-article-NSShttps://doaj.org/toc/1179-1608Jian-Xiong An,1– 3 John P Williams,4 Qi-Wu Fang,1 Yong Wang,1 Hui Liu,1 Le Shi,5 Wen-Hao Zhang1,2 1Department of Anesthesiology, Pain and Sleep Medicine, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing, People’s Republic of China; 2Savaid Medical School, University of Chinese Academy of Sciences, Beijing, People’s Republic of China; 3School of Medical Science & Engineering, Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing, People’s Republic of China; 4Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 5Key Laboratory of Mental Health, Peking University Sixth Hospital, Peking University Institute of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People’s Republic of ChinaCorrespondence: Wen-Hao Zhang Tel +86 159 1096 3901Email zhangwenhao18@mails.ucas.ac.cnBackground: Patient-controlled analgesia (PCA) is an “on-demand” system which allows patients to self-administer intravenous medications in small bolus doses. Based on the principles of PCA, we developed Patient-Controlled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (Dex), an alpha-2 agonist widely used for premedication, sedation, anxiolysis and analgesia. The purpose of this study was to assess the feasibility of the new method for the treatment of chronic intractable insomnia.Patients and Methods: Patients with chronic intractable insomnia undergoing PCSL (n=20) were evaluated with the Pittsburgh Sleep Quality Index (PSQI), Symptom Checklist 90 (SCL-90), Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) before and after the treatment. The patient characteristics, overall outcomes and related side effects were also assessed.Results: Fifteen patients completed the treatment protocol. The duration of PCSL varied from a few days to four months, and the dosage of Dex gradually decreased without eliciting signs or symptoms of tolerance or physical dependence. The sleep quality improvement occurred immediately after the therapy in 12/15 patients, and of which, 7/12 patients achieved continuously improved sleep quality in follow-up.Conclusion: PCSL with Dex might be a potential treatment for patients with chronic intractable insomnia. However, it is an off-label use, and the potential side effects of dexmedetomidine with long-term use needs further evaluation.Keywords: insomnia, dexmedetomidine, Patient-Controlled Sleep, biomimetic sleepAn JXWilliams JPFang QWWang YLiu HShi LZhang WHDove Medical Pressarticleinsomniadexmedetomidinepatient-controlled sleepPsychiatryRC435-571Neurophysiology and neuropsychologyQP351-495ENNature and Science of Sleep, Vol Volume 12, Pp 1033-1042 (2020)
institution DOAJ
collection DOAJ
language EN
topic insomnia
dexmedetomidine
patient-controlled sleep
Psychiatry
RC435-571
Neurophysiology and neuropsychology
QP351-495
spellingShingle insomnia
dexmedetomidine
patient-controlled sleep
Psychiatry
RC435-571
Neurophysiology and neuropsychology
QP351-495
An JX
Williams JP
Fang QW
Wang Y
Liu H
Shi L
Zhang WH
Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
description Jian-Xiong An,1– 3 John P Williams,4 Qi-Wu Fang,1 Yong Wang,1 Hui Liu,1 Le Shi,5 Wen-Hao Zhang1,2 1Department of Anesthesiology, Pain and Sleep Medicine, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing, People’s Republic of China; 2Savaid Medical School, University of Chinese Academy of Sciences, Beijing, People’s Republic of China; 3School of Medical Science & Engineering, Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing, People’s Republic of China; 4Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 5Key Laboratory of Mental Health, Peking University Sixth Hospital, Peking University Institute of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People’s Republic of ChinaCorrespondence: Wen-Hao Zhang Tel +86 159 1096 3901Email zhangwenhao18@mails.ucas.ac.cnBackground: Patient-controlled analgesia (PCA) is an “on-demand” system which allows patients to self-administer intravenous medications in small bolus doses. Based on the principles of PCA, we developed Patient-Controlled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (Dex), an alpha-2 agonist widely used for premedication, sedation, anxiolysis and analgesia. The purpose of this study was to assess the feasibility of the new method for the treatment of chronic intractable insomnia.Patients and Methods: Patients with chronic intractable insomnia undergoing PCSL (n=20) were evaluated with the Pittsburgh Sleep Quality Index (PSQI), Symptom Checklist 90 (SCL-90), Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) before and after the treatment. The patient characteristics, overall outcomes and related side effects were also assessed.Results: Fifteen patients completed the treatment protocol. The duration of PCSL varied from a few days to four months, and the dosage of Dex gradually decreased without eliciting signs or symptoms of tolerance or physical dependence. The sleep quality improvement occurred immediately after the therapy in 12/15 patients, and of which, 7/12 patients achieved continuously improved sleep quality in follow-up.Conclusion: PCSL with Dex might be a potential treatment for patients with chronic intractable insomnia. However, it is an off-label use, and the potential side effects of dexmedetomidine with long-term use needs further evaluation.Keywords: insomnia, dexmedetomidine, Patient-Controlled Sleep, biomimetic sleep
format article
author An JX
Williams JP
Fang QW
Wang Y
Liu H
Shi L
Zhang WH
author_facet An JX
Williams JP
Fang QW
Wang Y
Liu H
Shi L
Zhang WH
author_sort An JX
title Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
title_short Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
title_full Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
title_fullStr Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
title_full_unstemmed Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia
title_sort feasibility of patient-controlled sleep with dexmedetomidine in treating chronic intractable insomnia
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/7843809bcfcf4534b3a414c93de30206
work_keys_str_mv AT anjx feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT williamsjp feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT fangqw feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT wangy feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT liuh feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT shil feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
AT zhangwh feasibilityofpatientcontrolledsleepwithdexmedetomidineintreatingchronicintractableinsomnia
_version_ 1718394581196734464